Phase III Randomized Study of Rituximab/Carmustine, Etopo-side, Cytarabine, and Melphalan (BEAM) Compared With Iodine-131 Tositumomab/BEAM With Autologous Hematopoietic Cell Transplantation for Relapsed Diffuse Large B-Cell Lymphoma

Results From the BMT CTN 0401 Trial

Julie M. Vose, Shelly Carter, Linda J. Burns, Ernesto Ayala, Oliver W. Press, Craig Moskowitz, Edward A. Stadtmauer, Shin Mineshi, Richard Ambinder, Timothy Fenske, Mary Horowitz, Richard Fisher, Marcie Tomblyn

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

Purpose This clinical trial evaluated standard-dose radioimmunotherapy with a chemotherapy-based transplantation regimen followed by autologous hematopoietic cell transplantation versus rituximab with the same regimen in patients with relapsed diffuse large B-cell lymphoma (DLBCL). Patients and Methods Patients with chemotherapy-sensitive persistent or relapsed DLBCL were randomly assigned to receive iodine-131 tositumomab (dosimetric dose of 5 mCi on day 19 and therapeutic dose of 0.75 Gy on day 12), carmustine 300 mg/m2 (day 6), etoposide 100 mg/m2 twice daily (days 5 to 2), cytarabine 100 mg/m2 twice daily (days 5 to 2), and melphalan 140 mg/m2 (day 1; B-BEAM) or rituximab 375 mg/m2 on days 19 and 12 and the same chemotherapy regimen (R-BEAM). Results Two hundred twenty-four patients were enrolled, with 113 patients randomly assigned to R-BEAM and 111 patients assigned to B-BEAM. Two-year progression-free survival (PFS) rates, the primary end point, were 48.6% (95% CI, 38.6% to 57.8%) for R-BEAM and 47.9% (95% CI, 38.2% to 57%; P .94) for B-BEAM, and the 2-year overall survival (OS) rates were 65.6% (95% CI, 55.3% to 74.1%) for R-BEAM and 61% (95% CI, 50.9% to 69.9%; P .38) for B-BEAM. The 100-day treatment-related mortality rates were 4.1% (95% CI, 0.2% to 8.0%) for R-BEAM and 4.9% (95% CI, 0.8% to 9.0%; P .97) for B-BEAM. The maximum mucositis score was higher in the B-BEAM arm (0.72) compared with the R-BEAM arm (0.31; P .001). Conclusion The B-BEAM and R-BEAM regimens produced similar 2-year PFS and OS rates for patients with chemotherapy-sensitive relapsed DLBCL. No differences in toxicities other than mucositis were noted.

Original languageEnglish (US)
Pages (from-to)1662-1668
Number of pages7
JournalJournal of Clinical Oncology
Volume31
Issue number13
DOIs
StatePublished - May 1 2013
Externally publishedYes

Fingerprint

Carmustine
Melphalan
Lymphoma, Large B-Cell, Diffuse
Cytarabine
Cell Transplantation
Drug Therapy
Mucositis
Survival Rate
Disease-Free Survival
Radioimmunotherapy
Etoposide
Rituximab
trans-crotonin
iodine-131 anti-B1 antibody
Transplantation
Clinical Trials
Mortality
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Phase III Randomized Study of Rituximab/Carmustine, Etopo-side, Cytarabine, and Melphalan (BEAM) Compared With Iodine-131 Tositumomab/BEAM With Autologous Hematopoietic Cell Transplantation for Relapsed Diffuse Large B-Cell Lymphoma : Results From the BMT CTN 0401 Trial. / Vose, Julie M.; Carter, Shelly; Burns, Linda J.; Ayala, Ernesto; Press, Oliver W.; Moskowitz, Craig; Stadtmauer, Edward A.; Mineshi, Shin; Ambinder, Richard; Fenske, Timothy; Horowitz, Mary; Fisher, Richard; Tomblyn, Marcie.

In: Journal of Clinical Oncology, Vol. 31, No. 13, 01.05.2013, p. 1662-1668.

Research output: Contribution to journalArticle

Vose, Julie M. ; Carter, Shelly ; Burns, Linda J. ; Ayala, Ernesto ; Press, Oliver W. ; Moskowitz, Craig ; Stadtmauer, Edward A. ; Mineshi, Shin ; Ambinder, Richard ; Fenske, Timothy ; Horowitz, Mary ; Fisher, Richard ; Tomblyn, Marcie. / Phase III Randomized Study of Rituximab/Carmustine, Etopo-side, Cytarabine, and Melphalan (BEAM) Compared With Iodine-131 Tositumomab/BEAM With Autologous Hematopoietic Cell Transplantation for Relapsed Diffuse Large B-Cell Lymphoma : Results From the BMT CTN 0401 Trial. In: Journal of Clinical Oncology. 2013 ; Vol. 31, No. 13. pp. 1662-1668.
@article{a3cc1233cbaa493e81771b3796be5020,
title = "Phase III Randomized Study of Rituximab/Carmustine, Etopo-side, Cytarabine, and Melphalan (BEAM) Compared With Iodine-131 Tositumomab/BEAM With Autologous Hematopoietic Cell Transplantation for Relapsed Diffuse Large B-Cell Lymphoma: Results From the BMT CTN 0401 Trial",
abstract = "Purpose This clinical trial evaluated standard-dose radioimmunotherapy with a chemotherapy-based transplantation regimen followed by autologous hematopoietic cell transplantation versus rituximab with the same regimen in patients with relapsed diffuse large B-cell lymphoma (DLBCL). Patients and Methods Patients with chemotherapy-sensitive persistent or relapsed DLBCL were randomly assigned to receive iodine-131 tositumomab (dosimetric dose of 5 mCi on day 19 and therapeutic dose of 0.75 Gy on day 12), carmustine 300 mg/m2 (day 6), etoposide 100 mg/m2 twice daily (days 5 to 2), cytarabine 100 mg/m2 twice daily (days 5 to 2), and melphalan 140 mg/m2 (day 1; B-BEAM) or rituximab 375 mg/m2 on days 19 and 12 and the same chemotherapy regimen (R-BEAM). Results Two hundred twenty-four patients were enrolled, with 113 patients randomly assigned to R-BEAM and 111 patients assigned to B-BEAM. Two-year progression-free survival (PFS) rates, the primary end point, were 48.6{\%} (95{\%} CI, 38.6{\%} to 57.8{\%}) for R-BEAM and 47.9{\%} (95{\%} CI, 38.2{\%} to 57{\%}; P .94) for B-BEAM, and the 2-year overall survival (OS) rates were 65.6{\%} (95{\%} CI, 55.3{\%} to 74.1{\%}) for R-BEAM and 61{\%} (95{\%} CI, 50.9{\%} to 69.9{\%}; P .38) for B-BEAM. The 100-day treatment-related mortality rates were 4.1{\%} (95{\%} CI, 0.2{\%} to 8.0{\%}) for R-BEAM and 4.9{\%} (95{\%} CI, 0.8{\%} to 9.0{\%}; P .97) for B-BEAM. The maximum mucositis score was higher in the B-BEAM arm (0.72) compared with the R-BEAM arm (0.31; P .001). Conclusion The B-BEAM and R-BEAM regimens produced similar 2-year PFS and OS rates for patients with chemotherapy-sensitive relapsed DLBCL. No differences in toxicities other than mucositis were noted.",
author = "Vose, {Julie M.} and Shelly Carter and Burns, {Linda J.} and Ernesto Ayala and Press, {Oliver W.} and Craig Moskowitz and Stadtmauer, {Edward A.} and Shin Mineshi and Richard Ambinder and Timothy Fenske and Mary Horowitz and Richard Fisher and Marcie Tomblyn",
year = "2013",
month = "5",
day = "1",
doi = "10.1200/JCO.2012.45.9453",
language = "English (US)",
volume = "31",
pages = "1662--1668",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "13",

}

TY - JOUR

T1 - Phase III Randomized Study of Rituximab/Carmustine, Etopo-side, Cytarabine, and Melphalan (BEAM) Compared With Iodine-131 Tositumomab/BEAM With Autologous Hematopoietic Cell Transplantation for Relapsed Diffuse Large B-Cell Lymphoma

T2 - Results From the BMT CTN 0401 Trial

AU - Vose, Julie M.

AU - Carter, Shelly

AU - Burns, Linda J.

AU - Ayala, Ernesto

AU - Press, Oliver W.

AU - Moskowitz, Craig

AU - Stadtmauer, Edward A.

AU - Mineshi, Shin

AU - Ambinder, Richard

AU - Fenske, Timothy

AU - Horowitz, Mary

AU - Fisher, Richard

AU - Tomblyn, Marcie

PY - 2013/5/1

Y1 - 2013/5/1

N2 - Purpose This clinical trial evaluated standard-dose radioimmunotherapy with a chemotherapy-based transplantation regimen followed by autologous hematopoietic cell transplantation versus rituximab with the same regimen in patients with relapsed diffuse large B-cell lymphoma (DLBCL). Patients and Methods Patients with chemotherapy-sensitive persistent or relapsed DLBCL were randomly assigned to receive iodine-131 tositumomab (dosimetric dose of 5 mCi on day 19 and therapeutic dose of 0.75 Gy on day 12), carmustine 300 mg/m2 (day 6), etoposide 100 mg/m2 twice daily (days 5 to 2), cytarabine 100 mg/m2 twice daily (days 5 to 2), and melphalan 140 mg/m2 (day 1; B-BEAM) or rituximab 375 mg/m2 on days 19 and 12 and the same chemotherapy regimen (R-BEAM). Results Two hundred twenty-four patients were enrolled, with 113 patients randomly assigned to R-BEAM and 111 patients assigned to B-BEAM. Two-year progression-free survival (PFS) rates, the primary end point, were 48.6% (95% CI, 38.6% to 57.8%) for R-BEAM and 47.9% (95% CI, 38.2% to 57%; P .94) for B-BEAM, and the 2-year overall survival (OS) rates were 65.6% (95% CI, 55.3% to 74.1%) for R-BEAM and 61% (95% CI, 50.9% to 69.9%; P .38) for B-BEAM. The 100-day treatment-related mortality rates were 4.1% (95% CI, 0.2% to 8.0%) for R-BEAM and 4.9% (95% CI, 0.8% to 9.0%; P .97) for B-BEAM. The maximum mucositis score was higher in the B-BEAM arm (0.72) compared with the R-BEAM arm (0.31; P .001). Conclusion The B-BEAM and R-BEAM regimens produced similar 2-year PFS and OS rates for patients with chemotherapy-sensitive relapsed DLBCL. No differences in toxicities other than mucositis were noted.

AB - Purpose This clinical trial evaluated standard-dose radioimmunotherapy with a chemotherapy-based transplantation regimen followed by autologous hematopoietic cell transplantation versus rituximab with the same regimen in patients with relapsed diffuse large B-cell lymphoma (DLBCL). Patients and Methods Patients with chemotherapy-sensitive persistent or relapsed DLBCL were randomly assigned to receive iodine-131 tositumomab (dosimetric dose of 5 mCi on day 19 and therapeutic dose of 0.75 Gy on day 12), carmustine 300 mg/m2 (day 6), etoposide 100 mg/m2 twice daily (days 5 to 2), cytarabine 100 mg/m2 twice daily (days 5 to 2), and melphalan 140 mg/m2 (day 1; B-BEAM) or rituximab 375 mg/m2 on days 19 and 12 and the same chemotherapy regimen (R-BEAM). Results Two hundred twenty-four patients were enrolled, with 113 patients randomly assigned to R-BEAM and 111 patients assigned to B-BEAM. Two-year progression-free survival (PFS) rates, the primary end point, were 48.6% (95% CI, 38.6% to 57.8%) for R-BEAM and 47.9% (95% CI, 38.2% to 57%; P .94) for B-BEAM, and the 2-year overall survival (OS) rates were 65.6% (95% CI, 55.3% to 74.1%) for R-BEAM and 61% (95% CI, 50.9% to 69.9%; P .38) for B-BEAM. The 100-day treatment-related mortality rates were 4.1% (95% CI, 0.2% to 8.0%) for R-BEAM and 4.9% (95% CI, 0.8% to 9.0%; P .97) for B-BEAM. The maximum mucositis score was higher in the B-BEAM arm (0.72) compared with the R-BEAM arm (0.31; P .001). Conclusion The B-BEAM and R-BEAM regimens produced similar 2-year PFS and OS rates for patients with chemotherapy-sensitive relapsed DLBCL. No differences in toxicities other than mucositis were noted.

UR - http://www.scopus.com/inward/record.url?scp=84884202033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884202033&partnerID=8YFLogxK

U2 - 10.1200/JCO.2012.45.9453

DO - 10.1200/JCO.2012.45.9453

M3 - Article

VL - 31

SP - 1662

EP - 1668

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 13

ER -